Issued Patents All Time
Showing 1–23 of 23 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12234288 | Immunogenic arginase 2 polypeptides | — | 2025-02-25 |
| 12233103 | Indoleamine 2,3-dioxygenase based immunotherapy | Per Thor Straten | 2025-02-25 |
| 12215135 | PDL2 compounds | — | 2025-02-04 |
| 12194081 | ARGINASE1 polypeptides | — | 2025-01-14 |
| 12187782 | PDL1 peptides for use in cancer vaccines | — | 2025-01-07 |
| 11981944 | Immunogenic arginase peptides | — | 2024-05-14 |
| 11878053 | Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof | — | 2024-01-23 |
| 11648302 | Indoleamine 2,3-dioxygenase based immunotherapy | Per Thor Straten | 2023-05-16 |
| 11447537 | PDL2 compounds | — | 2022-09-20 |
| 11324813 | Indoleamine 2,3-dioxygenase based immunotherapy | Per Thor Straten | 2022-05-10 |
| 11298413 | Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof | — | 2022-04-12 |
| RE48522 | Survivin-derived peptides and uses thereof | Eivind Per Thor Straten | 2021-04-20 |
| 10858642 | Immunogenic arginase peptides | — | 2020-12-08 |
| 10736950 | Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof | — | 2020-08-11 |
| 10258678 | Indoleamine 2,3-dioxygenase based immunotherapy | Per Thor Straten | 2019-04-16 |
| 9669078 | PD-L1 based immunotherapy | — | 2017-06-06 |
| 9534030 | Survivin-derived peptides and uses thereof | Eivind Per Thor Straten | 2017-01-03 |
| 9433666 | Indoleamine 2,3-dioxygenase based immunotherapy | Per Thor Straten | 2016-09-06 |
| 9163077 | RhoC-based immunotherapy | Per Thor Straten | 2015-10-20 |
| 8318174 | Survivin-derived peptides and use thereof | Evind Per Thor Straten | 2012-11-27 |
| 7892559 | Survivin-derived peptides and use thereof | Eivind Per Thor Straten | 2011-02-22 |
| 7842294 | Proteins belonging to the Bcl-2 family and fragments thereof, and their use in cancer patients | Per Thor Straten | 2010-11-30 |
| 7687465 | Therapeutic cancer vaccine | Per Thor Straten | 2010-03-30 |